Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.